Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ASCO GU 2026 chart review compares ctDNA with serum markers in testicular cancer surveillance

An ASCO GU 2026 retrospective series of patients with testicular cancer who had at least one tumor-informed ctDNA result reported that, in that chart review, ctDNA was more sensitive and specific than serum tumor markers and imaging for residual disease and recurrence.

Journal of Clinical Oncology